Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia

Current Medical Research and Opinion

Volumn 28, Issue 1, 2012, Pages 57-67

  Bustos, Aurelia ^a   Álvarez, Ruth ^b   Aramburo, Pedro Miguel ^c   Carabantes, Francisco ^d   Díaz, Nieves ^e   Florin, Jesús ^f   Lázaro, Martn ^g   De Segovia, José María Martn ^h   Gasquet, José Antonio ⁱ   Alegre, Adrián ^j  

^a Clnica Vistahermosa   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c Hospital Rber Internacional   (Spain)

^d Hospital Carlos   (Spain)

^e HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^f HOSPITAL DE BARBASTRO   (Spain)

^g HOSPITAL XERAL CÍES   (Spain)

^h HOSPITAL MONTECELO   (Spain)

ⁱ Amgen SA   (Spain)

^j HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

more..

Author keywords

Anemia; Chemotherapy; Darbepoetin alfa; Hematologic malignancies; Solid tumors; Transfusion

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CHEMOTHERAPY INDUCED ANEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG DOSE INCREASE; DRUG EFFICACY; EDEMA; FEMALE; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; INFORMATION PROCESSING; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; PROSTATE CANCER; RETROSPECTIVE STUDY; THROMBOEMBOLISM; UROGENITAL TRACT CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855959625     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.639352     Document Type: Article

References (39)

1. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306 (Pubitemid 39348881)
2. Harper P, Littlewood T. Anaemia of cancer: impact on patient fatigue and longterm outcome. Oncology 2005;69(Suppl 2):2-7 (Pubitemid 41507248)
3. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-21 (Pubitemid 32552805)
4. Demetri GD. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 2001;84(Suppl 1):31-7 (Pubitemid 32453433)
5. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-95 (Pubitemid 34839682)
6. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26:132-49
7. Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008;13(Suppl 3):33-6
8. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28:4996
9. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007;11:1-202,iii-iv
10. Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006;3:CD003407
11. Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009;180:E62-71
12. Scrijvers D, Roila F. Erythropoiesis-stimulating agents in cancer patients: ESMO recommendations for use. Ann Oncol 2009;20(Suppl 4):159-61
13. Wauters I, Vansteenkiste J. Darbepoetin alfa in the treatment of chemotherapy-induced anaemia. Expert Opin Biol Ther 2009;9:221-30
14. Hedenus M, Vansteenkiste J, Kotasek D, et al. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 2005;23:6941-8
15. Ross SD, Allen IE, Henry DH, et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 2006;28:801-31 (Pubitemid 44062692)
16. Aapro M, Scherhag A, Burger HU. Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer 2008;99:14-22 (Pubitemid 351920217)
17. Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-76
18. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20 (Pubitemid 34993871)
19. Hedenus M, Hansen S, Taylor K, et al. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002;119:79-86 (Pubitemid 35176501)
20. Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-34 (Pubitemid 37297759)
21. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84(Suppl 1):3-10 (Pubitemid 32453429)
22. Jumbe N, Yao B, Rovetti R, et al. Clinical trial simulation of a 200-microg fixed dose of darbepoetin alfa in chemotherapy-induced anemia. Oncology (Williston Park) 2002;16(10 Suppl 11):37-44
23. Stevenson JG, Natale JJ. Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer. Pharmacotherapy 2007;27:434-46 (Pubitemid 46327910)
24. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Safety 1999;20:109-17 (Pubitemid 29101275)
25. Mel JR, Salar A, Rodriguez CA, et al. A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia. Curr Med Res Opin 2008;24:2931-42
26. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14 (Pubitemid 43821788)
27. Ludwig H, Crawford J, Osterborg A, et al. Pooled analysis of individual patientlevel data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009;27:2838-47
28. Shehata N, Walker I, Meyer R, et al. The use of erythropoiesis- stimulating agents in patients with non-myeloid hematological malignancies: a systematic review. Ann Hematol 2008;87:961-73
29. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24 (Pubitemid 351397066)
30. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-42
31. Patton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 2004;9:451-8 (Pubitemid 39014556)
32. Canon JL, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273-84 (Pubitemid 43264711)
33. Quirt I, Kovacs M, Couture F, et al. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience. Oncologist 2006;11:73-82 (Pubitemid 43152689)
34. Couture F, Turner AR, Melosky B, et al. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management. Oncologist 2005; 10:63-71 (Pubitemid 40171252)
35. Pat K, Anrys B, Verhulst D, et al. Observational Aranesp Survey to Investigate the Q3W Schedule (OASIS): a prospective observational study of treatment of chemotherapy-induced anaemia with every 3 weeks darbepoetin alfa. Support Care Cancer 2009;17:211-15
36. Charu V, Saidman B, Ben-Jacob A, et al. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. Oncologist 2007;12:1253-63 (Pubitemid 350106356)
37. Wun T, Law L, Harvey D, et al. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003; 98:1514-20 (Pubitemid 37151508)
38. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007;357:965-76 (Pubitemid 47367076)
39. Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009(3):CD007303